Flowonix Medical Partners with Miratech Medical for Distribution of Its Targeted Drug Delivery Products

Flowonix Medical and Miratech Medical today announced the acquisition of the U.S. distribution rights to Flowonix’s state-of-the-art targeted drug delivery system for the treatment of chronic pain and spasticity by Miratech Medical in a transaction that closed on May 11th. Miratech has long served as the exclusive agent for Flowonix products for certain markets, primarily in the Midwest.
“I am enthusiastic about this new agreement with an old friend of Flowonix,” stated Steve Adler, CEO of Flowonix. “We have worked together with Miratech very successfully in the past, and this new agreement expands and extends what has been a mutually beneficial relationship between our two organizations. This new business partnership has the potential to benefit millions of patients.”

As part of this new agreement, Miratech will become the sole U.S. distributor for Flowonix’s product line, including its flagship implantable drug infusion pump, the Prometra II. Furthermore, this new agreement gives Miratech full responsibility for U.S. commercial operations, including sales and marketing of products which will be led by Miratech’s senior leadership team Jimmie Nichols, its CEO, and Miratech COO, Matthew Cavacini. Miratech Medical will be relocating the headquarters of the commercial operation to Indianapolis, Indiana over the next few months.

“This agreement will unleash the full power of Flowonix, allowing us to realign our organization,” continued Steve Adler. “Flowonix will return to its original core values; we are the innovators, inventors, designers, and developers of world-class targeted drug delivery platforms. We will become the hub for pharmaceutical partnerships and will work on expanding indications for our products. Furthermore, this realignment dovetails with efforts already underway to expand distribution to underserved international markets. This is truly going to be an exciting new chapter in the Flowonix story, and expanded indications will bring the benefits of this life-changing therapy to patients around the world.” Miratech will absorb our experienced field service team and all related support operations. Their vast experience and service-oriented focus will ensure that Flowonix products are available to the many millions of patients who can benefit from them. The complete transition will occur over the next several months.

Jimmie Nichols, CEO of Miratech, added, “After ten wonderful years working alongside Flowonix, I am excited to announce the acquisition of Flowonix’s U.S. Commercial Operations. Miratech Medical’s offerings encompass a full interventional pain product portfolio, servicing to take Flowonix to an enhanced national level. From minimally invasive surgical spine products to peripheral and spinal cord neurostimulators, Miratech enhances the treatment potential for our physicians and their patients. In the Midwest, I’ve seen just how critical providing a full portfolio is in helping our physicians and patients reach their treatment goals. This partnership is a breakthrough for all of our patients nationwide, aiding our pursuit for the most beneficial interventional pain continuum.”

Earlier this year, Flowonix developed a remote service and support function for our customers covering the technical aspects of procedures such as MR imaging and pump refills. Remote support was successfully implemented in several geographical areas in the U.S. Coincident with this agreement, Flowonix and Miratech intend to expand this service throughout the U.S.

Flowonix Medical, with offices in Mount Olive, New Jersey and Mansfield, MA manufactures the Prometra II implantable infusion pump currently indicated for the treatment of pain and spasticity.

Miratech Medical is a diverse consulting team based in Indianapolis, Indiana, with deep experience and advanced skills related to cutting-edge medical devices and the conditions they treat. They partner with leading device companies to provide the skills and support needed to support clinical teams and their patients.